Holen Sie sich die Stockscreener-App
9.06
0.89%
0.08
Handel nachbörslich:
9.04
-0.02
-0.22%
Schlusskurs vom Vortag:
$8.98
Offen:
$9.2
24-Stunden-Volumen:
371.50K
Relative Volume:
1.40
Marktkapitalisierung:
$314.72M
Einnahmen:
$51.00M
Nettoeinkommen (Verlust:
$-8.73M
KGV:
-30.59
EPS:
-0.2962
Netto-Cashflow:
$-7.75M
1W Leistung:
+2.37%
1M Leistung:
-5.62%
6M Leistung:
+19.53%
1J Leistung:
+15.27%
1-Tages-Spanne:
$8.85
$9.31
1-Wochen-Bereich:
$8.83
$9.33
52-Wochen-Spanne:
$5.65
$10.45
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Firmenname
Fennec Pharmaceuticals Inc
Sektor
Branche
Telefon
(919) 636-4530
Adresse
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
9.06 | 314.72M | 51.00M | -8.73M | -7.75M | -0.2962 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Eingeleitet | B. Riley Securities | Buy |
| 2026-01-09 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-08 | Fortgesetzt | Craig Hallum | Buy |
| 2020-06-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-11 | Eingeleitet | Goldman | Buy |
Alle ansehen
Fennec Pharmaceuticals Inc Aktie (FENC) Neueste Nachrichten
Why Fennec Pharmaceuticals Inc stock is tanking today - Wealth Awesome
Fennec Pharmaceuticals Inc (FENC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why Fennec Pharmaceuticals Inc stock is gaining today - Wealth Awesome
Fennec Pharmaceuticals Inc (FENC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fennec Pharmaceuticals Inc (FENC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Why Fennec Pharmaceuticals Inc stock is rising today - Wealth Awesome
Fennec Pharmaceuticals Inc (FENC) Institutional Confidence - TradingKey
Fennec Pharmaceuticals Inc (FENC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fennec Pharmaceuticals Inc (FENC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fennec Pharmaceuticals Inc (FENC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fennec Pharmaceuticals Inc (FENC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fennec Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
Fennec Pharmaceuticals : Announces Results of Annual Meeting - marketscreener.com
New Fennec hire gets 10,000 stock options at $9, 10-year term - Stock Titan
FENC Q1 2026 Earnings: Surprise Profit as EPS of $0.01 Beats Estimates by 217.65%EPS Growth Report - newsline.com
FENC News | FENNEC PHARMACEUTICALS INC (NASDAQ:FENC) - ChartMill
Fennec Pharmaceuticals (FENC) Edges Higher as Biotech Sector Sees Mixed ActivityDelta Hedging - newsline.com
Fennec Shareholders Approve Governance, Compensation and Equity Plans - TipRanks
FENNEC (NASDAQ: FENC) director receives fully vested options for 20,000 shares - Stock Titan
Fennec Pharmaceuticals (NASDAQ: FENC) director granted 20,000 stock options at $8.70 - Stock Titan
FENNEC (FENC) director Khalid Islam receives options on 25,000 shares - Stock Titan
FENNEC (FENC) director Chris Rallis receives fully vested option grant - Stock Titan
Fennec (NASDAQ: FENC) investors back directors, pay and new equity plans - Stock Titan
Fennec Pharmaceuticals (FENC) Faces Modest Pullback: Key Levels to WatchWatchlist Stock Ideas - newsline.com
Fennec Announces Results of Annual Meeting - The Manila Times
Fennec investors re-elect directors, approve auditor and pay - Stock Titan
Technical Reactions to FENC Trends in Macro Strategies - Stock Traders Daily
Why Fennec Pharmaceuticals Inc stock is sliding today - Wealth Awesome
Insider Favorites High Growth Companies June 2026 - simplywall.st
ASCO 2026 drives scientific collaboration for Fennec Pharmaceuticals in hearing loss prevention research - Traders Union
Fennec Pharmaceuticals (NASDAQ: FENC) director exercises options, sells shares for tax obligations - Stock Titan
Insider sale notice: Rostislav Raykov to sell 9,747 shares (FENC) - Stock Titan
Fennec Pharmaceuticals (FENC) CSO gains 156 vested shares in Form 4 filing - Stock Titan
Fennec Pharmaceuticals (FENC) CCO awarded 168 common shares in Form 4 - Stock Titan
Fennec Pharmaceuticals (FENC) CMO receives 168-share grant, holds 21,015 - Stock Titan
Fennec Pharmaceuticals (FENC) CEO receives 1,159-share stock award - Stock Titan
Fennec (NASDAQ: FENC) CFO gains 1,703 shares as prior awards vest - Stock Titan
Trading the Move, Not the Narrative: (FENC) Edition - Stock Traders Daily
Fennec Pharmaceuticals targets cisplatin-induced hearing loss with new survivorship research at ASCO26 - Traders Union
Fennec Pharmaceuticals Inc.Common Stock (NQ: FENC - FinancialContent
Fennec Pharmaceuticals (FENC) Gains 1.7% as Shares Bounce Off Support — Key Levels in FocusStandard Deviation - The Legal Advocate
Fennec Pharmaceuticals Drives PEDMARK Sales as Q1 Revenue Hits Peak - HarianBasis.co
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter - Yahoo Finance
H.C. Wainwright raises Fennec Pharmaceuticals stock price target on growing adoption By Investing.com - Investing.com Australia
Fennec Showcases New PEDMARK Data at ASCO 2026 - TipRanks
New PEDMARK studies at 2026 ASCO showcased by Fennec (NASDAQ: FENC) - Stock Titan
Maxim Group Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Maintains Target Price $15 - Moomoo
H.C. Wainwright raises Fennec Pharmaceuticals stock price target on growing adoption - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Fennec Announces New Research Supporting Pedmark's Use at ASCO Annual Meeting - Moomoo
H.C. Wainwright Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Raises Target Price to $16 - Moomoo
Finanzdaten der Fennec Pharmaceuticals Inc-Aktie (FENC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):